HOSPITAL UNIVERSITARIO QUIRÓNSALUD MADRID
Departamento
Hospital de Fuenlabrada
Fuenlabrada, EspañaPublicaciones en colaboración con investigadores/as de Hospital de Fuenlabrada (18)
2022
-
Defining a Standard Set of Patient-Reported Outcomes for Patients With Advanced Ovarian Cancer
Frontiers in Oncology, Vol. 12
-
Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A
Nature Communications, Vol. 13, Núm. 1
2020
-
High-dose neoadjuvant chemoradiotherapy versus chemotherapy alone followed by surgery in potentially-resectable stage IIIA-N2 NSCLC. A multi-institutional retrospective study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society)
Reports of Practical Oncology and Radiotherapy, Vol. 25, Núm. 3, pp. 447-455
-
Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial
Breast Cancer Research, Vol. 22, Núm. 1
-
Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)
Breast, Vol. 54, pp. 286-292
-
Phase III study to evaluate patient’s preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07)
European Journal of Cancer Care, Vol. 29, Núm. 4
2019
-
Nintedanib plus letrozole in early breast cancer: A phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition
Breast Cancer Research, Vol. 21, Núm. 1
-
Prognostic factors in neoadjuvant treatment followed by surgery in stage IIIA-N2 non-small cell lung cancer: a multi-institutional study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society)
Clinical and Translational Oncology, Vol. 21, Núm. 6, pp. 735-744
-
Quantitative assessment of interstitial lung disease in Sjögren’s syndrome
PLoS ONE, Vol. 14, Núm. 11
-
Systemic manifestations of primary Sjögren's syndrome out of the ESSDAI classification: Prevalence and clinical relevance in a large international, multi-ethnic cohort of patients
Clinical and Experimental Rheumatology, Vol. 37, pp. S97-S106
-
The Big Data Sjögren consortium: A project for a new data science era
Clinical and Experimental Rheumatology, Vol. 37, pp. S19-S23
2018
-
Addition of durvalumab (Dur) upon progression to bevacizumab (Bev) maintenance in advanced HER2-negative (HERNEG) breast cancer (BC): Safety, efficacy and biomarkers
Annals of Oncology, Vol. 29, pp. ix24
-
How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: Analysis of 10,500 patients (Sjögren Big Data Project)
Clinical and Experimental Rheumatology, Vol. 36, pp. S102-S111
-
Importance of 68Ga-PSMA PET/CT in hospital practice. View of the radiation oncologist
Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 37, Núm. 5, pp. 302-314
-
Neoadjuvant treatment followed by surgery versus definitive chemoradiation in stage IIIA-N2 non-small-cell lung cancer: A multi-institutional study by the oncologic group for the study of lung cancer (Spanish Radiation Oncology Society)
Lung Cancer, Vol. 118, pp. 119-127
-
Severe, life-threatening phenotype of primary Sjögren's syndrome: Clinical characterisation and outcomes in 1580 patients (the GEAS-SS Registry)
Clinical and Experimental Rheumatology, Vol. 36, pp. S121-S129
2017
-
Characterization and risk estimate of cancer in patients with primary Sjögren syndrome
Journal of Hematology and Oncology, Vol. 10, Núm. 1
-
Magnetic resonance imaging for prostate cancer before radical and salvage radiotherapy: What radiation oncologists need to know
World Journal of Clinical Oncology, Vol. 8, Núm. 4, pp. 305-319